Cerevel Therapeutics Holdings Inc (NASDAQ: CERE)’s stock price has decreased by -0.38 compared to its previous closing price of 44.62. However, the company has seen a 2.33% increase in its stock price over the last five trading sessions. accesswire.com reported 2024-07-01 that LOS ANGELES, CA / ACCESSWIRE / July 1, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Cerevel Therapeutics Holdings, Inc. (“Cerevel” or “the Company”) (NASDAQ:CERE) for potential breaches of fiduciary duty on the part of its directors and management. The investigation focuses on determining if the Cerevel board breached its fiduciary duties to shareholders.
Is It Worth Investing in Cerevel Therapeutics Holdings Inc (NASDAQ: CERE) Right Now?
The stock has a 36-month beta value of 1.40. Opinions on the stock are mixed, with 0 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for CERE is 87.51M, and at present, short sellers hold a 6.83% of that float. On July 29, 2024, the average trading volume of CERE was 1.77M shares.
CERE’s Market Performance
The stock of Cerevel Therapeutics Holdings Inc (CERE) has seen a 2.33% increase in the past week, with a 9.75% rise in the past month, and a 4.66% gain in the past quarter. The volatility ratio for the week is 0.88%, and the volatility levels for the past 30 days are at 2.17% for CERE. The simple moving average for the past 20 days is 5.83% for CERE’s stock, with a 15.92% simple moving average for the past 200 days.
Analysts’ Opinion of CERE
Many brokerage firms have already submitted their reports for CERE stocks, with TD Cowen repeating the rating for CERE by listing it as a “Market Perform.” The predicted price for CERE in the upcoming period, according to TD Cowen is $45 based on the research report published on December 08, 2023 of the previous year 2023.
JP Morgan, on the other hand, stated in their research note that they expect to see CERE reach a price target of $25. The rating they have provided for CERE stocks is “Neutral” according to the report published on November 20th, 2023.
Piper Sandler gave a rating of “Overweight” to CERE, setting the target price at $33 in the report published on September 28th of the previous year.
CERE Trading at 7.23% from the 50-Day Moving Average
After a stumble in the market that brought CERE to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -0.47% of loss for the given period.
Volatility was left at 2.17%, however, over the last 30 days, the volatility rate increased by 0.88%, as shares surge +8.78% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +5.13% upper at present.
During the last 5 trading sessions, CERE rose by +2.39%, which changed the moving average for the period of 200-days by +96.03% in comparison to the 20-day moving average, which settled at $42.18. In addition, Cerevel Therapeutics Holdings Inc saw 4.83% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at CERE starting from COLES N ANTHONY, who sale 25,000 shares at the price of $41.18 back on Jul 01 ’24. After this action, COLES N ANTHONY now owns 25,928 shares of Cerevel Therapeutics Holdings Inc, valued at $1,029,535 using the latest closing price.
COLES N ANTHONY, the Director of Cerevel Therapeutics Holdings Inc, sale 50,000 shares at $40.61 during a trade that took place back on Jun 03 ’24, which means that COLES N ANTHONY is holding 15,638 shares at $2,030,520 based on the most recent closing price.
Stock Fundamentals for CERE
Current profitability levels for the company are sitting at:
- -59.47 for the present operating margin
- 0.29 for the gross margin
The net margin for Cerevel Therapeutics Holdings Inc stands at -55.84. The total capital return value is set at -0.47. Equity return is now at value -92.45, with -44.76 for asset returns.
Based on Cerevel Therapeutics Holdings Inc (CERE), the company’s capital structure generated 0.39 points at debt to capital in total, while cash flow to debt ratio is standing at -1.0. The debt to equity ratio resting at 0.65. The interest coverage ratio of the stock is -46.34.
Currently, EBITDA for the company is -441.64 million with net debt to EBITDA at -0.1. When we switch over and look at the enterprise to sales, we see a ratio of 987.26. The receivables turnover for the company is 1.66for trailing twelve months and the total asset turnover is 0.01. The liquidity ratio also appears to be rather interesting for investors as it stands at 10.22.
Conclusion
To sum up, Cerevel Therapeutics Holdings Inc (CERE) has seen a better performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
